European journal of rheumatology最新文献

{"title":"After-Ultrasound Blind Injections: Relics of Musculoskeletal Medicine or Lack Thereof.","authors":"Levend Karaçoban, Levent Özçakar","doi":"10.5152/eurjrheum.2023.22124","DOIUrl":"10.5152/eurjrheum.2023.22124","url":null,"abstract":"Corresponding author: Levend Karaçoban E-mail: leven dkara coban @gmai l.com Received: December 12, 2022 Accepted: July 28, 2023 Publication Date: September 1, 2023 Musculoskeletal physicians are dealing with various problems in their daily clinical practice. Among the other treatment modalities, joint and soft tissue interventions are commonplace. These injections may be used for several purposes and via different techniques owing to the physicians’ expertise and past education. Herein, it is noteworthy that ultrasound (US) provides a pivotal role as “guidance” throughout the whole management process.1 Although there is still a need for further high(er) level evidence comparisons between US-guided vs. blind injections; in this short paper, we would like to underscore some issues concerning the overall contribution of US in the treatment of different scenarios.","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 3","pages":"120-121"},"PeriodicalIF":1.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/95/ejr-10-3-120.PMC10544163.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10553361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucocorticoid-Induced Osteoporosis: Increased Awareness as a Management Strategy for Prevention of this Complication in Patients with Systemic Autoimmune Rheumatic Disease.","authors":"Adegbenga Bankole,&nbsp;Emma L Greear","doi":"10.5152/eurjrheum.2023.22086","DOIUrl":"10.5152/eurjrheum.2023.22086","url":null,"abstract":"<p><strong>Background: </strong>It has been estimated that about 1% of the US population is treated with long-term glucocorticoids. High doses of glucocorticoids particularly those used by rheumatologists and oth- ers for systemic autoimmune rheumatic disease result in bone loss, causing glucocorticoid-induced osteoporosis and an increase in the risk of fractures. The increased risk is related to both the daily dose and the cumulative dose of the glucocorticoids. Despite the availability of effective preventative and treatment options, glucocorticoid-induced osteoporosis is often not mitigated with the use of these preventive therapies. The risk of glucocorticoid-induced osteoporosis often also goes under- recognized, because it occurs in a different group of patients compared to age-related osteoporosis. As a result, glucocorticoid-induced osteoporosis is not always treated until after fractures may have occurred. Our objective is to determine if a structured health-care provider's educational interven- tion with intermittent educational updates would lead to improvement in the identification, evalu- ation, and prevention of glucocorticoid-induced osteoporosisin those patients at the highest risk of glucocorticoid-induced osteoporosis.</p><p><strong>Methods: </strong>In this single-center, prospective study, patients over 40 years of age, receiving a total cumu- lative dose of glucocorticoids of >5 g or a single dose of >30 mg of prednisone or its equivalent was enrolled. All providers attended an academic Journal Club, where the current American College of Rheumatology guidelines regarding glucocorticoid-induced osteoporosiswas reviewed. All providers received monthly reminders during academic meetings within the department.</p><p><strong>Results: </strong>There was a statistically significant improvement between pre- and post-educational data, with increasing use of glucocorticoid-induced osteoporosis preventive measures, which was sus- tained over the 12-month duration of the study.</p><p><strong>Conclusion: </strong>This research shows the importance of provider education as a means of disseminating information and improving the quality of patient care.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 3","pages":"97-100"},"PeriodicalIF":1.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/d1/ejr-10-3-97.PMC10543380.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10535711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phosphate Nephropathy in a Patient with Takayasu Arteritis.","authors":"İrem Biçer,&nbsp;Rıza Can Kardaş,&nbsp;Betül Öğüt Cimer,&nbsp;İpek Işık,&nbsp;Hamit Küçük","doi":"10.5152/eurjrheum.2023.23011","DOIUrl":"10.5152/eurjrheum.2023.23011","url":null,"abstract":"hosphate nephropathy can cause acute and chronic kidney damage and develops due to the use of sodium phosphate-containing oral preparations used in colonoscopy preparation. Mild to moderate proteinuria may be seen in acute phosphate nephropathy","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 3","pages":"114-115"},"PeriodicalIF":1.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/8b/ejr-10-3-114.PMC10544357.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10177284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Response to Treatment Using Doppler Signal Positivity Measured by Ultrasound in Rheumatoid Arthritis: A Proof-of-Concept Study.","authors":"Ummugulsum Gazel,&nbsp;Gizem Ayan,&nbsp;Dilek Solmaz,&nbsp;Nancy Maltez,&nbsp;Tim Ramsay,&nbsp;Antonio R Cabral,&nbsp;Servet Akar,&nbsp;Sibel Zehra Aydin,&nbsp;Jacob Karsh","doi":"10.5152/eurjrheum.2023.23005","DOIUrl":"10.5152/eurjrheum.2023.23005","url":null,"abstract":"linically active rheumatoid arthritis (RA) patients whose synovitis scores on ultrasound (US) were higher at baseline were shown to respond better to enhancements in RA therapies. 1-3","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 3","pages":"118-119"},"PeriodicalIF":1.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/22/ejr-10-3-118.PMC10544597.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10180763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matrix Metalloproteinase-2 and -3 Levels in Patients with Behçet's Disease and Implication for the Presence of Vascular Aneurysm or Neurologic Involvement.","authors":"Pinar Talu Erten,&nbsp;Gökhan Keser,&nbsp;Raika Durusoy,&nbsp;Sinem Burcu Kocaer,&nbsp;Kenan Aksu","doi":"10.5152/eurjrheum.2023.23007","DOIUrl":"10.5152/eurjrheum.2023.23007","url":null,"abstract":"<p><strong>Background: </strong>Behçet's disease is a systemic vasculitis affecting both arteries and veins, as well as caus- ing recurrent inflammatory multiorgan disease. Vascular involvement is associated with increased mortality and morbidity. Matrix metalloproteinases are released at sites of inflammation and degrade various components of the extracellular matrix. Increased levels of metalloproteinase-9 and metal- loproteinase-2 have been previously reported in Behçet's disease.</p><p><strong>Methods: </strong>In this cross-sectional study, metalloproteinase-2 and metalloproteinase-3 serum levels were investigated in 103 patients with Behçet's disease and 69 healthy controls, using Invitrogen immunoassay human metalloproteinase-2 and metalloproteinase-3 ELISA kits.</p><p><strong>Results: </strong>Serum metalloproteinase-2 and metalloproteinase-3 levels were significantly higher in the Behçet's disease group compared to healthy controls. Besides, serum metalloproteinase-3 levels were significantly higher in subgroups of Behçet's disease with aneurysmal vascular involvement and with neurological involvement. However, metalloproteinase-2 and metalloproteinase-3 serum levels did not show a positive correlation with disease activity.</p><p><strong>Conclusion: </strong>Metalloproteinase-2 and -3 may contribute to the complex pathogenesis of Behçet's dis- ease. More importantly, the detection of very high serum levels of metalloproteinase-3 may predict the formation of an aneurysm, or possibly the presence of neurological involvement in Behçet's dis- ease and may lead the clinician to make an earlier diagnosis of these complications in young male patients with high risk.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 3","pages":"101-106"},"PeriodicalIF":1.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/91/ejr-10-3-101.PMC10543994.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10553367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship Between Sarcopenic Obesity and Knee Osteoarthritis: The SARCOB Study.","authors":"Sarah Razaq,&nbsp;Murat Kara,&nbsp;Levent Özçakar","doi":"10.5152/eurjrheum.2023.22085","DOIUrl":"10.5152/eurjrheum.2023.22085","url":null,"abstract":"<p><strong>Background: </strong>To investigate whether sarcopenic obesity may contribute to knee osteoarthritis or not.</p><p><strong>Methods: </strong>In this study, we assessed 140 community-dwelling adult patients. Their demographic data were recorded along with comorbidities. Anterior mid-thigh muscle thickness in the axial plane was measured on the dominant leg using ultrasound midway between the anterior superior iliac spine and the upper end of patella in millimeter. Then, the sonographic thigh adjustment ratio was calcu- lated by dividing this thickness by body mass index. ISarcoPRM algorithm was used for the diagnosis of sarcopenia. Kellgren-Lawrence grading was used for knee osteoarthritis . Functional evaluation was performed using chair stand test, gait speed, and grip strength.</p><p><strong>Results: </strong>There were 50 patients with knee osteoarthritis and 90 age- and gender-similar control sub- jects. When compared with controls, anterior thigh muscle thickness, gait speed, and grip strength were found to be similar between the groups, whereas body mass index and chair stand test val- ues were higher in the knee osteoarthritis group (both P < .05). In addition, sarcopenic obesity was observed in 12 (13.3%) of control subjects and in 14 (28%) of osteoarthritis patients. When age, gen- der, exercise, smoking, and body composition type (i.e., nonsarcopenic nonobese, sarcopenic only, obese only, and sarcopenic obesity) were taken into binary logistic regression analyses, only sarcope- nic obesity [relative risk ratio = 2.705 (95% CI: 1.079-6.779)] was independently related with the knee osteoarthritis (P < .05).</p><p><strong>Conclusion: </strong>Our preliminary study has shown that neither sarcopenia nor obesity but sarcopenic obe- sity seems to be independently related to the knee osteoarthritis. Further longitudinal studies with larger samples are required for investigating the effects of obesity and sarcopenia on the develop- ment of knee osteoarthritis.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 3","pages":"92-96"},"PeriodicalIF":1.9,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/97/ejr-10-3-92.PMC10544641.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10182423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B-Scan Ultrasound Evaluation for Uveitis in Inflammatory Arthropathies: Systematic Review.","authors":"José Alexandre Mendonça,&nbsp;Rafael de Figueiredo Torres Caivano,&nbsp;Isabella Casani Rech,&nbsp;Isabella Siste de Almeida Aoki,&nbsp;Caique Chagas Cavuto","doi":"10.5152/eurjrheum.2023.22054","DOIUrl":"10.5152/eurjrheum.2023.22054","url":null,"abstract":"<p><p>The ocular inflammatory process may be associated with autoimmune inflammatory joint damage and can be better recovered by B-mode ultrasound, being little explored in the absent eye evaluation. This study aimed to conduct a systematic review using the Patients or Problem, Intervention, Control or Comparison, Outcomes strategy: uveitis; ultrasound, arthritis, and diagnosis. Clinical trials, meta-analysis, and randomized controlled trials that specifically address the scope of this study will be evaluated. For the search in the database, a choice of controlled vocabulary will be used with the MEDLINE MeSH platform (Medical Subject Headings). The articles must be dated from the year 2010 until the year 2020. To charting methods will be used Preferred Reporting Items for Systematic Reviews and Meta-Analyses Flow Diagram and risk of bias: the Cochrane risk of bias tool. Grade of recommendation assessment: Grading of Recommendations Assessment, Development, and Evaluation Group guidelines. Of 2909 studies, only 13 studies were included, which evaluated the use of B-mode ultrasound to assess anterior and intermediate uveitis and complications, and 5 cases showed an association of vitreitis. B-mode ultrasound can be an important benefit of complementing clinical evaluation in patients with the uveal inflammatory process associated with several autoimmune arthropathies, but more studies with better-elaborated methodology design will be necessary.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"71-83"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/57/ejr-10-2-71.PMC10544347.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9824659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients.","authors":"Sinakhanım Huseynzada,&nbsp;Tuba Yüce İnel,&nbsp;Farid Hajiyev,&nbsp;Aydan Köken Avşar,&nbsp;Ali Balcı,&nbsp;Hale Akpınar,&nbsp;Fatoş Önen,&nbsp;İsmail Sarı","doi":"10.5152/eurjrheum.2023.22049","DOIUrl":"10.5152/eurjrheum.2023.22049","url":null,"abstract":"<p><strong>Objective: </strong>Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect, systemic immunosuppression is not expected, and this may have a negative effect on the extra-intestinal symptoms of inflammatory bowel disease, particularly spondyloarthritis. Currently, there is limited data regarding the effect of vedolizumab on spondyloarthritis symptoms. We aimed to investigate whether vedolizumab has an effect on the occurrence of rheumatological symptoms and the clinical course of patients who have spondyloarthritis.</p><p><strong>Methods: </strong>Thirty-nine adult inflammatory bowel disease patients who were followed up in the Gastroenterology Clinic and treated with vedolizumab were included in the study. Patients were reviewed in terms of rheumatological manifestations. The occurrence of new musculoskeletal findings during the vedolizumab treatment was recorded. Patients with a former diagnosis of spondyloarthritis were evaluated for the activity of axial and peripheral manifestations during the vedolizumab.</p><p><strong>Results: </strong>There were 39 inflammatory bowel disease patients (29 Crohn's disease, 10 ulcerative colitis, 48.7% (n = 19) male) who had been treated with vedolizumab. The mean age of the patients was 41.4 ± 15.7 years, and the duration of inflammatory bowel disease was 10.4 ± 7.5 years. A total of 17 (44%) patients had accompanying spondyloarthritis findings (mean age 47.08 ± 15.325 years and 58.8% M). Seven patients had axial dominant symptoms and 6 of them were in an active disease state before vedolizumab. During vedolizumab, all but 1 continued to be active. There were 14 patients with arthritis/arthralgias before vedolizumab and only 3 had improvement with therapy. On the other hand, there were 3 patients who had new-onset arthralgias/arthritis with vedolizumab. In total, 6 patients needed to stop vedolizumab because of spondyloarthritis activation (n = 2) and uncontrolled inflammatory bowel disease (n = 4), respectively.</p><p><strong>Conclusion: </strong>Treatment with vedolizumab seems no effect on both the occurrence and the course of rheumatological manifestations in inflammatory bowel disease patients. Further studies are required to replicate our results.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"50-56"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/7c/ejr-10-2-50.PMC10542484.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9831562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound Examination for a Traumatic Thumb Injury: Simple and Straightforward.","authors":"Berkay Yalçınkaya,&nbsp;Hasan Ocak,&nbsp;Pelin Analay,&nbsp;Levent Özçakar","doi":"10.5152/eurjrheum.2023.23006","DOIUrl":"10.5152/eurjrheum.2023.23006","url":null,"abstract":"Corresponding author: Berkay Yalçınkaya E-mail: berkay0lka@gmail.com Received: January 21, 2023 Accepted: May 09, 2023 Publication Date: July 13, 2023 A 29-year-old man (psychiatry resident) was seen for acute right-hand pain on the thenar side. He described the pain to have ensued after a fall episode 3 days ago (during walking). He declared that the pain was worse upon palpation and during hand movements. He denied any neurological symptoms and the rest of his medical history was noncontributory.","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"90-91"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/c2/ejr-10-2-90.PMC10544409.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9828300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoglobulin G4-Associated Rosai-Dorfman Disease: Report of 3 Cases.","authors":"Jesica Romina Gallo,&nbsp;Sergio Paira,&nbsp;Gabriela Hernández-Molina,&nbsp;Jesús Delgado-de la Mora,&nbsp;Daniel Montante-Montes de Oca,&nbsp;Eduardo Martín-Nares","doi":"10.5152/eurjrheum.2023.22064","DOIUrl":"10.5152/eurjrheum.2023.22064","url":null,"abstract":"<p><p>Rosai-Dorfman disease is characterized by dilated lymph node sinuses filled with lymphocytes, plasma cells, and histiocytes. Many of these histiocytes classically exhibit emperipolesis of lymphocytes and plasma cells. Abundant immunoglobulin G4+ plasma cells occur in some cases, and a potential relationship with immunoglobulin G4-related disease has been suggested. Here, we report 3 cases of immunoglobulin G4-associated Rosai-Dorfman disease. Immunoglobulin G4-related disease was suspected based on immunoglobulin G4+ plasma cell infiltration, but the final diagnosis was immunoglobulin G4-associated Rosai-Dorfman disease. At present, the evidence does not support a link between immunoglobulin G4-associated Rosai-Dorfman disease and immunoglobulin G4-related disease, and one condition should not be considered part of the spectrum of the other. We believe it is of paramount importance to increase the awareness of immunoglobulin G4-associated Rosai-Dorfman disease for pathologists who interpret the biopsies and clinicians who integrate the diagnosis and treat such patients to not overdiagnose immunoglobulin G4-related disease.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 2","pages":"57-61"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/42/ejr-10-2-57.PMC10543072.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9832052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}